|
Theratechnologies is pepped up on peptides. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. Lead drug candidate tesamorelin is a growth hormone-releasing peptide that Theratechnologies believes can combat a variety of problems, including HIV-related lipodystrophy (the metabolic syndrome characterized by changes in distribution of adipose tissue), muscle wasting associated with chronic obstructive pulmonary disease, sleep maintenance insomnia, and immune dysfunction in elderly patients.
|
| | | Contact Information | |
Address: |
2310 Alfred-Nobel Blvd.
Saint-Laurent, Quebec H4S 2A4, Canada
| | Phone: | 514-336-7800 | | Fax: | 514-336-7242 |
|
| Financial
Highlights | | Fiscal Year End: | November | | Revenue (2008): | 2.10 M | | Revenue Growth (1 yr): | (-32.70%) | | Employees (2008): | 98 | | Employee Growth (1 yr): | 55.60% |
|
|
Key People
| | • |
Chairman:
Paul Pommier
| | • |
President, CEO, and Director:
Yves Rosconi
| | • |
SEVP, CFO, and Director:
Luc Tanguay
|
|
|
